A new agent for the treatment of patients with myelodysplastic syndrome
In a paper published this week in PLoS Medicine, Azra Raza and colleagues (University of Massachusetts) use gene expression profiling to identify a molecular signature that predicts response to lenalidomide in patients without chromosome 5q deletions. This suggests that these patients have a defect in erythroid differentiation.
In a related review article, Jerry Radich (Fred Hutchinson Cancer Research Center, Seattle, USA) reviews key research on the biology underlying treatment response in myelodysplasia, including Raza and colleagues' new study.
Citation: Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, et al. (2008) An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 5(2): e35.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE
VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050035
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-raza.pdf
CONTACT:
Azra Raza
University of Massachusetts
Division of Hematology Oncology
Worcester, MA 01605
United States of America
araza@aptiumoncology.com
Related PLoS Medicine perspective article:
Citation: Radich J (2008) Solving the mystery of myelodysplasia. PLoS Med 5(2): e40
VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050040
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-radich.pdf
Jerry Radich
Fred Hutchinson Cancer Research Center
Clinical Research Division
Seattle, Washington
United States of America
+1 206-667-4118
jradich@fhcrc.org
FROM THE PLoS MEDICINE MAGAZINE SECTION:
Salivating for knowledge: potential pharmacological agents in tick saliva
Joppe Hovius (University of Amsterdam) and colleagues review anticoagulant and immunosuppressive proteins present in tick saliva, and discuss how immunologically targeting such molecules could prevent transmission of tick-borne pathogens.
Citation: Hovius JWR, Levi M, Fikrig E (2008) Salivating for knowledge: Potential pharmacological agents in tick saliva. PLoS Med 5(2): e43.
VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050043
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-hovius.pdf
Joppe Hovius
University of Amsterdam, AMC
Center for Experimental and Molecular Medicine
Meibergdreef 9
Amsterdam, Noord-Holland 1105 AZ
Netherlands
+31205666034
+31206977192 (fax)
j.w.hovius@amc.uva.nl
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org
Everything published by PLoS Medicine is Open Access: freely available for anyone to read, download, redistribute and otherwise use, as long as the authorship is properly attributed.
PLOS Medicine